| Literature DB >> 25511737 |
Wen-Ting Liu1, Ying-Ying Jing1, Guo-Feng Yu2, Zhi-Peng Han1, Dan-Dan Yu1, Qing-Min Fan1, Fei Ye1, Rong Li1, Lu Gao1, Qiu-Dong Zhao1, Meng-Chao Wu3, Li-Xin Wei4.
Abstract
Cancer stem cells (CSCs) or tumor-initiating cells (TICs), a small subset of tumor cells, are involved in tumor initiation, progression, recurrence and metastasis. In human hepatocellular carcinoma (HCC), TICs are enriched with cell surface markers and play a key role in chemotherapy resistance, tumor invasion and migration. Toll like receptor 4 (TLR4), acting as a receptor for lipopolysaccharide (LPS), has been reported to be responsible for carcinogenesis, invasion, metastasis and cancer progression. In our study, two HCC cell lines and a splenic vein metastasis of the nude mouse model were used to study the invasive ability of TLR4 positive HCC cells in vitro and in vivo. Stem-like features were also detected in TLR4 positive HCC cells. A total of 88 clinical samples from HCC patients were used to evaluate the association of TLR4 and stem-cell marker expression, and the relationship between TLR4 expression and clinicopathological characteristics was analyzed. The in vitro and in vivo experiments indicated that TLR4 positive HCC cells displayed significantly enhanced invasion and migration, and stem-like properties were also detected in TLR4 positive HCC cells. Clinically, TLR4 expression levels were found to be significantly higher in HCC tissues with microvascular invasion. Additionally, high expression of TLR4 in HCC tissues was strongly associated with both early recurrence and poor survivals in patients. Our results indicated that there was a relationship between TLR4 expression and CSC's features, TLR4 may act as a CSC marker, prompting tumor invasion and migration, which contributes to the poor prognosis of HCC.Entities:
Keywords: Hepatocellular carcinoma; Toll like receptor 4; Tumor invasion and migration; Tumor-initiating cells
Mesh:
Substances:
Year: 2014 PMID: 25511737 DOI: 10.1016/j.canlet.2014.12.019
Source DB: PubMed Journal: Cancer Lett ISSN: 0304-3835 Impact factor: 8.679